(Q39092622)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Stéphane Germain

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

6

Christophe Leboeuf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

12

Anne Janin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

9

Philippe Bertheau

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

Mariana Varna

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

Guilhem Bousquet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

7

Cédric de Bazelaire

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

5

Pierre Mongiat-Artus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Irmine Ferreira

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Li Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Eric Raymond

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

24 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1183-1193

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Exploring the role of novel agents in the treatment of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

VEGFR2 translocates to the nucleus to regulate its own transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2300-0

10.1007/S00280-013-2300-0

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24061866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference